SAPPHIRE reported a statistically significant motor-function difference for the pooled apitegromab groups versus placebo in its primary younger SMA population. The result is a disease-specific functional finding, not a percentage increase in muscle strength.[1]
- Study phase
- Phase 3
- Participants
- 188; primary group 156
- Endpoint
- HFMSE change at 12 months
Who participated and what was measured?
The phase 3 trial enrolled 188 nonambulatory participants with type 2 or 3 SMA receiving nusinersen or risdiplam. The primary analysis population comprised 156 participants aged 2–12 years. The outcome was change in the Hammersmith Functional Motor Scale–Expanded (HFMSE) at 12 months.[1]
An outcome scale is a defined instrument. Its points should remain points; translating them into a percentage of “strength gained” changes the meaning.
What was the reported result?
The pooled apitegromab comparison produced a 1.8-point greater HFMSE change than placebo (95% confidence interval 0.30–3.32; p=0.019). The separately tested higher-dose group did not reach statistical significance.[1]
This distinction is central. A pooled analysis and a separate treatment-arm analysis are not interchangeable conclusions. A summary should name the comparison that generated the estimate rather than assigning the same result to every arm.
How does the 2026 approval change the context?
FDA approved Isembyld (apitegromab-mstn) in September 2026 for SMA in adults and children aged 2 years or older receiving an SMN2-targeted treatment.[2] The label includes a fracture warning and other safety information.[3]
The publication and the regulatory label serve different purposes. The paper describes a study; the label defines an approved indication and prescribing information. A current clinical summary should keep both available.
What should a reader avoid concluding?
Do not extend a finding from a specific neuromuscular-disease population to healthy-athlete performance. Do not assume that evidence for one antibody validates a retail peptide. Those are different interventions and different questions.
This study is useful for learning how an endpoint, population, and analysis plan constrain a conclusion. See how to read myostatin trials for a reusable framework.
Questions, answered.
Does 1.8 points mean 1.8% stronger?
No. It is a difference on the HFMSE motor-function scale, not a percentage strength change.
Did every apitegromab comparison reach significance?
No. The pooled comparison did; the separately tested higher-dose comparison did not in the published primary analysis.
Sources & further reading
Primary research and official records used for this page. Study results apply to the populations and interventions described.
- Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE)Crawford et al. · Lancet Neurology · 2025 · Phase 3 randomized trial
- FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular AtrophyU.S. Food and Drug Administration · September 2026 · Official approval announcement
- Isembyld (apitegromab-mstn) prescribing informationFDA-hosted prescribing information · Revised September 2026 · PDF